CA2251742A1 - Drug complex - Google Patents
Drug complexInfo
- Publication number
- CA2251742A1 CA2251742A1 CA002251742A CA2251742A CA2251742A1 CA 2251742 A1 CA2251742 A1 CA 2251742A1 CA 002251742 A CA002251742 A CA 002251742A CA 2251742 A CA2251742 A CA 2251742A CA 2251742 A1 CA2251742 A1 CA 2251742A1
- Authority
- CA
- Canada
- Prior art keywords
- drug
- group
- spacer
- carboxyl group
- carrier
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
Disclosed is a drug complex of a drug having a hydroxyl group, which is capable of controlling the rate of the release of the drug therefrom in blood, the drug complex being represented by the following formula (1):
A-B-C (1) wherein A represents at least one carrier selected from the group consisting of saccharides each having a car-boxyl group, polyethylene glycols each having a carboxyl group, aliphatic carboxylic acids each having a carboxyl group, and derivatives thereof each having a carboxyl group; B represents at least one spacer comprised of a compound having a amino group and a carboxyl group; C
represents at least one drug having a hydroxyl group, wherein the carrier A is bonded to the spacer B through an amide bond formed between the carboxyl group of the carrier A and the amino group of the spacer B; and the spacer B is bonded to the drug C through an ester bond formed between the carboxyl group of the spacer B and the hydroxyl group of the drug C. The drug complex of the present invention is capable of not only surely controlling the rate of release of the drug therefrom, but also enhancing the transferability of the drug to target tissues and the pharmacological effect of the drug.
A-B-C (1) wherein A represents at least one carrier selected from the group consisting of saccharides each having a car-boxyl group, polyethylene glycols each having a carboxyl group, aliphatic carboxylic acids each having a carboxyl group, and derivatives thereof each having a carboxyl group; B represents at least one spacer comprised of a compound having a amino group and a carboxyl group; C
represents at least one drug having a hydroxyl group, wherein the carrier A is bonded to the spacer B through an amide bond formed between the carboxyl group of the carrier A and the amino group of the spacer B; and the spacer B is bonded to the drug C through an ester bond formed between the carboxyl group of the spacer B and the hydroxyl group of the drug C. The drug complex of the present invention is capable of not only surely controlling the rate of release of the drug therefrom, but also enhancing the transferability of the drug to target tissues and the pharmacological effect of the drug.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP11525796 | 1996-04-15 | ||
JP8-115257 | 1996-04-15 | ||
JP32588096 | 1996-11-22 | ||
JP8-325880 | 1996-11-22 | ||
PCT/JP1997/001303 WO1997038727A1 (en) | 1996-04-15 | 1997-04-15 | Medicament composite |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2251742A1 true CA2251742A1 (en) | 1997-10-23 |
CA2251742C CA2251742C (en) | 2001-12-11 |
Family
ID=26453799
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002251742A Expired - Fee Related CA2251742C (en) | 1996-04-15 | 1997-04-15 | Drug complex |
Country Status (7)
Country | Link |
---|---|
US (1) | US6458347B1 (en) |
EP (1) | EP0895784B1 (en) |
JP (2) | JP4420472B2 (en) |
AT (1) | ATE310538T1 (en) |
CA (1) | CA2251742C (en) |
DE (1) | DE69734709D1 (en) |
WO (1) | WO1997038727A1 (en) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997038727A1 (en) * | 1996-04-15 | 1997-10-23 | Asahi Kasei Kogyo Kabushiki Kaisha | Medicament composite |
US6541508B2 (en) | 1999-09-13 | 2003-04-01 | Nobex Corporation | Taxane prodrugs |
US6380405B1 (en) | 1999-09-13 | 2002-04-30 | Nobex Corporation | Taxane prodrugs |
US6713454B1 (en) | 1999-09-13 | 2004-03-30 | Nobex Corporation | Prodrugs of etoposide and etoposide analogs |
CN101816794A (en) * | 2001-06-25 | 2010-09-01 | 味之素株式会社 | Antitumor agent |
TWI313609B (en) * | 2001-08-21 | 2009-08-21 | Mitsubishi Tanabe Pharma Corp | Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor |
DE10209821A1 (en) | 2002-03-06 | 2003-09-25 | Biotechnologie Ges Mittelhesse | Coupling of proteins to a modified polysaccharide |
DE10324710A1 (en) | 2003-05-30 | 2004-12-16 | Supramol Parenteral Colloids Gmbh | Starch derivative Complex |
WO2005014655A2 (en) | 2003-08-08 | 2005-02-17 | Fresenius Kabi Deutschland Gmbh | Conjugates of hydroxyalkyl starch and a protein |
US7282590B2 (en) * | 2004-02-12 | 2007-10-16 | The Research Foundation Of State University Of New York | Drug conjugates |
RU2375384C2 (en) | 2004-09-22 | 2009-12-10 | Ниппон Каяку Кабусики Кайся | New block copolymer, micellar preparation and anticarcinogenic agent containing micellar preparation as active component |
US9603941B2 (en) * | 2006-01-24 | 2017-03-28 | Minghui Chai | Method of preparing dendritic drugs |
US8323669B2 (en) | 2006-03-28 | 2012-12-04 | Nippon Kayaku Kabushiki Kaisha | Polymer conjugate of taxane |
US8940332B2 (en) | 2006-05-18 | 2015-01-27 | Nippon Kayaku Kabushiki Kaisha | High-molecular weight conjugate of podophyllotoxins |
US20080108138A1 (en) * | 2006-06-13 | 2008-05-08 | Vermette Patrick | Bioactive compositions and their use in cell patterning |
JP5548364B2 (en) * | 2006-10-03 | 2014-07-16 | 日本化薬株式会社 | Polymer conjugates of resorcinol derivatives |
US8334364B2 (en) | 2006-11-06 | 2012-12-18 | Nipon Kayaku Kabushiki Kaisha | High-molecular weight derivative of nucleic acid antimetabolite |
US8188222B2 (en) | 2006-11-08 | 2012-05-29 | Nippon Kayaku Kabushiki Kaisha | High molecular weight derivative of nucleic acid antimetabolite |
USRE46190E1 (en) | 2007-09-28 | 2016-11-01 | Nippon Kayaku Kabushiki Kaisha | High-molecular weight conjugate of steroids |
EP2258397B1 (en) | 2008-03-18 | 2017-10-11 | Nippon Kayaku Kabushiki Kaisha | Polymer conjugate of physiologically active substance |
WO2009136572A1 (en) | 2008-05-08 | 2009-11-12 | 日本化薬株式会社 | Polymer conjugate of folic acid or folic acid derivative |
CN102421827B (en) | 2009-05-15 | 2014-07-30 | 日本化药株式会社 | Polymer conjugate of bioactive substance having hydroxy group |
WO2012067138A1 (en) | 2010-11-17 | 2012-05-24 | 日本化薬株式会社 | Novel polymer derivative of cytidine metabolism antagonist |
WO2013035641A1 (en) | 2011-09-11 | 2013-03-14 | 日本化薬株式会社 | Method for manufacturing block copolymer |
JP6453214B2 (en) * | 2013-07-10 | 2019-01-16 | 生化学工業株式会社 | Glycosaminoglycan derivative and method for producing the same |
US10675354B2 (en) | 2013-07-10 | 2020-06-09 | Seikagaku Corporation | Glycosaminoglycan derivative and method for producing same |
WO2015071841A1 (en) | 2013-11-12 | 2015-05-21 | Druggability Technologies Holdings Limited | Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6067503A (en) * | 1983-09-24 | 1985-04-17 | Kyowa Hakko Kogyo Co Ltd | Compound binding mitomycin with polysaccharide |
GB8500209D0 (en) | 1985-01-04 | 1985-02-13 | Ceskoslovenska Akademie Ved | Synthetic polymeric drugs |
AU4406793A (en) * | 1992-06-04 | 1993-12-30 | Clover Consolidated, Limited | Water-soluble polymeric carriers for drug delivery |
GB9213077D0 (en) | 1992-06-19 | 1992-08-05 | Erba Carlo Spa | Polymerbound taxol derivatives |
DE4236237A1 (en) | 1992-10-27 | 1994-04-28 | Behringwerke Ag | Prodrugs, their preparation and use as medicines |
US5646176A (en) | 1992-12-24 | 1997-07-08 | Bristol-Myers Squibb Company | Phosphonooxymethyl ethers of taxane derivatives |
WO1994019376A1 (en) * | 1993-02-26 | 1994-09-01 | Drug Delivery System Institute, Ltd. | Polysaccharide derivative and drug carrier |
US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
AU8052194A (en) | 1993-10-20 | 1995-05-08 | Enzon, Inc. | 2'- and/or 7- substituted taxoids |
US5760072A (en) * | 1995-12-29 | 1998-06-02 | Pharmachemie B.V. | Paclitaxel prodrugs, method for preparation as well as their use in selective chemotherapy |
ATE314843T1 (en) * | 1996-03-12 | 2006-02-15 | Pg Txl Co Lp | WATER SOLUBLE PACLITAXEL PRODRUGS |
WO1997038727A1 (en) * | 1996-04-15 | 1997-10-23 | Asahi Kasei Kogyo Kabushiki Kaisha | Medicament composite |
-
1997
- 1997-04-15 WO PCT/JP1997/001303 patent/WO1997038727A1/en active IP Right Grant
- 1997-04-15 DE DE69734709T patent/DE69734709D1/en not_active Expired - Lifetime
- 1997-04-15 AT AT97915728T patent/ATE310538T1/en not_active IP Right Cessation
- 1997-04-15 CA CA002251742A patent/CA2251742C/en not_active Expired - Fee Related
- 1997-04-15 EP EP97915728A patent/EP0895784B1/en not_active Expired - Lifetime
- 1997-04-15 JP JP53695197A patent/JP4420472B2/en not_active Expired - Fee Related
-
1998
- 1998-10-14 US US09/172,085 patent/US6458347B1/en not_active Expired - Lifetime
-
2009
- 2009-09-08 JP JP2009206567A patent/JP2009287036A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CA2251742C (en) | 2001-12-11 |
EP0895784A1 (en) | 1999-02-10 |
WO1997038727A1 (en) | 1997-10-23 |
JP2009287036A (en) | 2009-12-10 |
EP0895784A4 (en) | 2003-03-19 |
ATE310538T1 (en) | 2005-12-15 |
EP0895784B1 (en) | 2005-11-23 |
US6458347B1 (en) | 2002-10-01 |
JP4420472B2 (en) | 2010-02-24 |
DE69734709D1 (en) | 2005-12-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2251742A1 (en) | Drug complex | |
EP0979648A3 (en) | Microspheres of esters of hyaluronic acid for controlled release of an active | |
GR3034416T3 (en) | Polysaccharide derivative and drug carrier. | |
CA2057099A1 (en) | Bile acid derivatives, process for their preparation and use of these compounds as pharmaceuticals | |
CA2150287A1 (en) | Agent for treating hepato-biliary diseases | |
CA2212856A1 (en) | Benzopyran-containing compounds and method for their use | |
ES2158537T3 (en) | DERIVATIVES OF CYCLOPROPILALCANOIC ACIDS. | |
WO2001019407A3 (en) | Taxane prodrugs | |
CA2127463A1 (en) | Biodegradable polymers for cell transplantation | |
EP0930309A4 (en) | Taxane derivatives and drugs containing the same | |
CA2304809A1 (en) | Process for the preparation of hydroxy substituted gamma butyrolactones | |
CA2195677A1 (en) | Endothelin antagonists | |
EP0664289A3 (en) | Isoquinolines | |
WO1999024076A3 (en) | Salicylate derivatized therapeutic and diagnostic agents | |
AU5696094A (en) | Hydroxyiminoalkylindole carboxylic acid derivatives used as antagonists of excitatory amino acids | |
WO2001012233A3 (en) | Sustained release formulation of a peptide | |
WO1999006397A3 (en) | Pyrrolidine-3-carboxylic acid derivatives and their use as endothelin antagonists | |
NZ223287A (en) | 4-thiazolidine carboxylic acid derivatives and pharmaceutical compositions | |
WO1989005580A1 (en) | Improvements in or relating to avian control | |
CA2046861A1 (en) | K2p pro stabilisation | |
WO1994008586A3 (en) | Azido derivatives of cyclopentane heptanoic or heptenoic acid | |
CA2046929A1 (en) | T-pa pro stabilisation | |
AU5814696A (en) | The preparation of carboxylic acid derivatives | |
JPS5615256A (en) | Novel tetrapeptide derivative | |
CA2111830A1 (en) | Flexible Polyamide Film |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20170418 |